Pharmaceutical

Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment. What To Know: The therapy, a long-acting, peptide-antibody conjugate administered...

Novartis AG (NYSE:NVS) on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5 therapies...

After Donald Trump signed an executive order slashing drug prices last week, experts have highlighted how pharmacy benefit managers (PBMs) could be hit the hardest despite pharmaceutical companies facing the potential of compressed margins amid poor pricing power. What Happened: According to Thomas...

The U.S. Food and Drug Administration on Tuesday approved AbbVie Inc.’s (NYSE:ABBV) Rinvoq (upadacitinib), 15 mg, once daily, for giant cell arteritis (GCA). GCA is an inflammation of blood vessels, called arteries, in and around the scalp. Earlier in April, the European Commission approved...

Eli Lilly And Co (NYSE:LLY) is scheduled to report its quarterly results on Thursday. The company is likely to report its first-quarter results in line with peers, with some tariff and policy-related commentary during the earnings call, according to Goldman Sachs. The Eli Lilly Analyst: Analyst...

Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....

A physician survey for Neurocrine Biosciences Inc's (NASDAQ:NBIX) Crenessity suggests "strong uptake across all patient segments," according to Needham.  The Neurocrine Biosciences Analyst: Analyst Ami Fadia upgraded the rating from Hold to Buy, while raising the price target to $138. The...

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs. What Happened: The rally in pharma stocks was short-lived after the stocks reversed course...

Tempest Therapeutics, Inc. (NASDAQ:TPST) said on Thursday it had retained MTS Health Partners as a financial advisor. The company plans to explore strategic alternatives to advance its clinical-stage programs and maximize stockholder value. Strategic alternatives may include M&A, partnerships,...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized myasthenia gravis (MG). MG is a chronic autoimmune disorder that causes muscle weakness and fatigue...

Sangamo Therapeutics Inc (NASDAQ:SGMO) shares are surging in Thursday’s after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co (NYSE:LLY). What Happened: Sangamo Therapeutics entered into a license agreement with Eli Lilly, granting the...

Edgewise Therapeutics, Inc., (NASDAQ:EWTX) on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM). HCM is a genetic heart condition where the heart muscle thickens, making...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, including of explanted devices. Vertex completed enrollment and...